Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Provided By GlobeNewswire
Last update: Oct 16, 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents
2.64
-0.1 (-3.65%)
Find more stocks in the Stock Screener
SPRO Latest News and Analysis
5 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
6 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
7 days ago - ChartmillThese stocks are making the most noise in today's session.Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
